As a global authority in personalized medicine research and care, the Mayo Clinic Center for Individualized Medicine brings together knowledge and innovation from around the world. The center collaborates with academic experts, start-ups, established industry leaders and research nonprofits to develop precision medicine technology and translate it into world-class patient care.
Research teams combine multiomic technologies and data to develop precision diagnostics and therapeutics for patients with various types of cancers, rare genetic diseases, unique pharmacogenomic needs and other clinical challenges. Dynamic collaborations accelerate this process, bringing more options, faster, to patients who need them.
Team science is integral to research at Mayo Clinic, and individualized medicine is no exception. The Center for Individualized Medicine's collaborative research extends beyond the walls of Mayo Clinic in a shared drive to connect hubs of expertise, develop cures for devastating diseases and transform care for patients worldwide.
Arizona State University
The Center for Individualized Medicine and Arizona State University (ASU) are working together on many fronts, including an initiative to jointly fund research projects that lead to commercialization opportunities. The first two $100,000 grants aided in the launch of EndoVantage.
Other collaborative activities include:
- Funding several research studies with Mayo Clinic and ASU investigators, including a biomarker discovery project focused on protein microarray signatures for the detection of colorectal cancer
- Funding a mass spectrometer for research into metallomics-related biomarkers
Mayo Clinic collaborates with Genentech, a research-based global pharmaceutical and biopharmaceutical company. Genentech strives to set the standard for quality, safety and value in the discovery, development and manufacture of medicines for patients and physicians. Mayo Clinic and Genentech are committed to supporting collaborative research through the Genentech Research Fund in Individualized Medicine, supporting research to improve health care quality and clinical outcomes.
Gerstner Family Career Development Awards
The Gerstner Family Foundation established the Gerstner Family Career Development Awards in Individualized Medicine so that early career investigators receive important seed money to conduct research to predict, prevent, treat and cure disease using individualized medicine approaches.
Learn more about the Gerstner Family Career Development Awards.
Mayo Clinic collaborates with Helix, a population genomics company, to sequence participants' DNA to study the benefits of having patients' DNA sequencing data before they have a specific health concern. This work is part of Mayo Clinic GeneGuide's strategy to promote population genetic health. Mayo Clinic is committed to improving health outcomes and accelerating research through population genomics.
Helix's clinical Exome+ sequencing technology reads all 20,000 genes that code for proteins, plus hundreds of thousands of informative regions outside protein-coding areas of the exome.
The Mayo Clinic GeneGuide Laboratory reviews a subset of this data, looking at genes related to hereditary breast, ovarian and colorectal cancers in addition to genes related to familial hypercholesterolemia. The remainder of the data is saved to Mayo Clinic's omics data platform for future use in clinical care, research and education.
Mayo Clinic & Illinois Alliance for Technology-Based Healthcare
The Mayo Clinic & Illinois Alliance for Technology-Based Healthcare was founded in 2010 by Mayo Clinic and the University of Illinois at Urbana Champaign (UIUC) to advance research and clinical treatment options related to individualized medicine. It consists of:
- Integrated research activities focusing on information-based medicine, genomics and point-of-care diagnostics
- Entrepreneurial efforts to ensure full deployment and commercialization of educational and research outcomes
- Innovative educational programs to train the next generation of clinicians and biomedical scientists
Specific collaborative activities include:
The Center for Individualized Medicine is accelerating discovery and translation of microbiome diagnostics and therapies for a range of diseases through collaborations with:
- DayTwo (Adanim, Israel)
- Evelo Biosciences (Cambridge, Massachusetts)
- Novome Biotechnologies (San Francisco)
- Pendulum (San Francisco)
- Second Genome (San Francisco)
- Seres Health (Cambridge, Massachusetts)
Oneome is a Minneapolis-based genomics interpretation company that exports Mayo Clinic's extensive pharmacogenomics knowledge in the form of concise and actionable reports to help providers deliver the right medication at the right time. OneOme reports focus on providing pharmacogenomically driven guidance for medications with high levels of evidence in the medical literature.
Regeneron Genetics Center
Mayo Clinic collaborates with Regeneron Genetics Center, a leading science and technology company, to generate exome sequencing and genotype data on 125,000 DNA samples from participants in research studies at Mayo Clinic, including the Mayo Clinic Biobank. This collaboration, called Project Generation, will result in one of the most comprehensive genomics databases in the world, and will enable researchers to learn more about how genes affect health and disease.
Translational Genomics Research Institute (TGen)
Investigators from Mayo Clinic and TGen, a Phoenix-based nonprofit research organization, have developed extensive individualized medicine-based collaborations spanning a variety of diseases, including multiple myeloma, breast cancer, melanoma, squamous cell carcinoma and pancreatic cancer.
As part of these collaborations, some Mayo Clinic and TGen researchers have received joint academic appointments at each other's organizations.